INTRODUCTION:
Cone photoreceptors in the human retina enable daytime, color, and highacuity vision. The three subtypes of human cones are defined by the visual pigment that they express: blue-opsin (short wavelength; S), greenopsin (medium wavelength; M), or red-opsin (long wavelength; L). Mutations that affect opsin expression or function cause various forms of color blindness and retinal degeneration. RATIONALE: Our current understanding of the vertebrate eye has been derived primarily from the study of model organisms. We studied the human retina to understand the developmental mechanisms that generate the mosaic of mutually exclusive cone subtypes. Specification of human cones occurs in a two-step process. First, a decision occurs between S versus L/M cone fates. If the L/M fate is chosen, a subsequent choice is made between expression of L-or Mopsin. To determine the mechanism that controls the first decision between S and L/M cone fates, we studied human retinal organoids derived from stem cells. RESULTS: We found that human organoids and retinas have similar distributions, gene expression profiles, and morphologies of cone subtypes. During development, S cones are specified first, followed by L/M cones. This temporal switch from specification of S cones to generation of L/M cones is controlled by thyroid hormone (TH) signaling. In retinal organoids that lacked thyroid hormone receptor b (Thrb), all cones developed into the S subtype. Thrb binds with high affinity to triiodothyronine (T3), the more active form of TH, to regulate gene expression. We observed that addition of T3 early during development induced L/M fate in nearly all cones. Thus, TH signaling through Thrb is necessary and sufficient to induce L/M cone fate and suppress S fate. TH exists largely in two states: thyroxine (T4), the most abundant circulating form of TH, and T3, which binds TH receptors with high affinity. We hypothesized that the retina itself could modulate TH levels to control subtype fates. We found that deiodinase 3 (DIO3), an enzyme that degrades both T3 and T4, was expressed early in organoid and retina development. Conversely, deiodinase 2 (DIO2), an enzyme that converts T4 to active T3, as well as TH carriers and transporters, were expressed later in development. Temporally dynamic expression of TH-degrading and -activating proteins supports a model in which the retina itself controls TH levels, ensuring low TH signaling early to specify S cones and high TH signaling later in development to produce L/M cones.
CONCLUSION: Studies of model organisms and human epidemiology often generate hypotheses about human biology that cannot be studied in humans. Organoids provide a system to determine the mechanisms of human development, enabling direct testing of hypotheses in developing human tissue. Our studies identify temporal regulation of TH signaling as a mechanism that controls cone subtype specification in humans. Consistent with our findings, preterm human infants with low T3 and T4 have an increased incidence of color vision defects. Moreover, our identification of a mechanism that generates one cone subtype while suppressing the other, coupled with successful transplantation and incorporation of stem cell-derived photoreceptors in mice, suggests that the promise of therapies to treat human diseases such as color blindness, retinitis pigmentosa, and macular degeneration will be achieved in the near future. ▪ 1 of 1 The mechanisms underlying specification of neuronal subtypes within the human nervous system are largely unknown. The blue (S), green (M), and red (L) cones of the retina enable high-acuity daytime and color vision. To determine the mechanism that controls S versus L/M fates, we studied the differentiation of human retinal organoids. Organoids and retinas have similar distributions, expression profiles, and morphologies of cone subtypes. S cones are specified first, followed by L/M cones, and thyroid hormone signaling controls this temporal switch. Dynamic expression of thyroid hormone-degrading and -activating proteins within the retina ensures low signaling early to specify S cones and high signaling late to produce L/M cones. This work establishes organoids as a model for determining mechanisms of human development with promising utility for therapeutics and vision repair.
C one photoreceptors in the human retina enable daytime, color, and high-acuity vision (1) . The three subtypes of human cones are defined by the visual pigment that they express: blue-opsin (short wavelength; S), green-opsin (medium wavelength; M), or redopsin (long wavelength; L) (2) . Specification of human cones occurs in a two-step process. First, a decision occurs between S versus L/M cone fates ( Fig. 1A ). If the L/M fate is chosen, a subsequent choice is made between expression of L-or Mopsins (3) (4) (5) (6) . Mutations that affect opsin expression or function cause various forms of color blindness and retinal degeneration (7) (8) (9) . Great progress has been made in our understanding of the vertebrate eye through the study of model organisms. However, little is known about the developmental mechanisms that generate the mosaic of mutually exclusive cone subtypes in the human retina. We studied the specification of human cone subtypes using human retinal organoids differentiated from stem cells ( Fig. 1 , D to K).
Human retinal organoids generate photoreceptors that respond to light (10) (11) (12) (13) (14) . We found that human organoids recapitulate the specification of cone subtypes observed in the human ret-ina, including the temporal generation of S cones followed by L and M cones. Moreover, we found that this regulation is controlled by thyroid hormone signaling, which is necessary and sufficient to control cone subtype fates through the nuclear hormone receptor thyroid hormone receptor b (Thrb). Expression of thyroid hormone-regulating genes suggests that retina-intrinsic temporal control of thyroid hormone levels and activity governs cone subtype specification. Whereas retinal organoids have largely been studied for their promise of therapeutic applications (15) , our work demonstrates that human organoids can also be used to reveal fundamental mechanisms of human development.
Specification of cone cells in organoids recapitulates development in the human retina
We compared features of cone subtypes in human organoids with those of adult retinal tissue. Adult human retinas and organoids at day 200 of differentiation displayed similar ratios of S to L/M cones as indicated by expression of S-or L/Mopsins (adult, S = 13%, L/M = 87%; organoid, S = 29%, L/M = 71%) ( Fig. 1, B and C, and fig. S1A). The difference in the ratios is likely due to the immaturity of the organoid at~6 months compared with the terminally differentiated adult retina. We examined L/M cones with an antibody that recognizes both L-and M-opsin proteins because of their extremely high similarity. Both S and L/M cones expressed the cone-rod-homeobox transcription factor (CRX), a critical transcription factor for photoreceptor differentiation (Fig. 2 , A and E) (16) (17) (18) , indicating proper fate specification in organoids. Additionally, cones in organoids and retinas displayed similar morphologies, with L/M cones that had longer outer segments and wider inner segments than those of S cones (Fig. 2, B to D and F to H) (19) . The outer segments of cones were shorter in organoids than in adult retinas, which is consistent with postnatal maturation (Fig. 2 , D and H) (20) . Thus, cone subtypes in human retinal organoids displayed distributions, gene expression patterns, and morphologies similar to those of cones of the human retina.
We next examined the developmental dynamics of cone subtype specification in organoids. In the human retina, S cones are generated during fetal weeks 11 to 34 (days 77 to 238), whereas L/M cones are specified later, during fetal weeks 14 to 37 (days 98 to 259) (21, 22) . We tracked the ratios and densities of S and L/M cones in organoids by means of antibody staining over 360 days of differentiation. Cones expressing S-opsin were first observed at day 150 ( Fig. 2 We next conducted RNA sequencing (RNAseq) through 250 days of induced pluripotent stem cell (iPSC)-derived organoid development. We found that S-opsin RNA was expressed first at day 111 and leveled off at day 160, whereas L/Mopsin RNA was expressed at day 160 and remained steady after day 180, which is consistent with the timeline of photoreceptor maturation in organoids and fetal retinas ( Fig. 2N and fig. S1B ). Moreover, CRX RNA and CRX protein were expressed before opsins in organoids, which is similar to human development ( Fig. 2N and fig. S1 , B to G) (23) . Thus, human organoids recapitulate many aspects of the developmental timeline of cone subtype specification observed in human retinas, providing a model system with which to uncover the mechanisms of these developmental changes.
Thyroid hormone signaling and the temporal switch between S and L/M fate specification
Seminal work in mice identified Thrb2 as a critical regulator of cone subtype specification: Thrb2 mutants display a complete loss of M-opsin expression and a complete gain of S-opsin expression in cone photoreceptors (24) (25) (26) . Similar roles for Thrb2 have been characterized in other organisms with highly divergent cone patterning (27) (28) (29) . Additionally, rare human mutations in Thrb2 are reported to alter color perception, which is indicative of a change in the S-to-L/M cone ratio (30) . To directly test the role of Thrb2 in human cone subtype specification, we used CRISPR/Cas9 in human embryonic stem cells (ESCs) to generate a homozygous mutation that resulted in early translational termination in the 1 of 7 first exon of Thrb2 ( fig. S2A) . Surprisingly, organoids derived from these mutant stem cells displayed no differences in cone subtype ratio from genotypically wild-type organoids [wild type, S = 62%, L/M = 38%; Thrb2 knockout (KO), S = 59%, L/M = 41%; P = 0.83]. The S-to-L/M ratio is high for both wild-type controls and Thrb2 KO organoids, likely owing to variability in organoid differentiation. Thus, unlike previous suggestions based on other species, Thrb2 is dispensable for cone subtype specification in humans ( Fig. 3 , A to C).
Because Thrb2 alone is not required for human cone subtype specification, we reexamined data from Weiss et. al (30) and found that missense mutations in exons 9 and 10 affected both Thrb2 and another isoform of the human Thrb gene, Thrb1 ( fig. S2A ). Thus, we asked whether Thrb1 and Thrb2 together are required for cone subtype specification in humans. To completely ablate Thrb function (Thrb1 and Thrb2), we used CRISPR/Cas9 in human ESCs to delete a shared exon that codes for part of the DNA binding domain of Thrb ( fig. S2A ). Thrb null mutant retinal organoids displayed a complete conversion of all cones to the S subtype (wild type, S = 27%, L/M = 73%; Thrb KO, S = 100%, L/M = 0%; P < 0.0001) ( Fig. 3 , D to E and H). In these mutants, all cones expressed S-opsin and had the S cone morphology (Fig. 3, I and J) . Thus, Thrb is required to activate L/M and to repress S cone fates in the human retina.
Thrb binds with high affinity to triiodothyronine (T3), the more active form of thyroid hormone, to regulate gene expression (31) . Depletion or addition of T3 alters the ratios of S to M cones in rodents (25, 32, 33) . Because L/M cones differentiate after S cones, we hypothesized that T3 acts through Thrb late in retinal development to induce L/M cone fate and repress S cone fate. One prediction of this hypothesis is that addition of T3 early in development will induce L/M fate and repress S fate. To test this model, we added 20 nM T3 to ESC-and iPSC-derived organoids starting from days 20 to 50 and continued until day 200 of differentiation. We observed a dramatic conversion of cone cells to L/M fate (wild type, S = 27%, L/M = 73%; wild type + T3, S = 4%, L/M = 96%; P < 0.01) (Fig. 3, F  and H, and fig. S2B ). Thus, early addition of T3 is sufficient to induce L/M fate and suppress S fate.
To test whether T3 acts specifically through Thrb to control cone subtype specification, we differentiated Thrb mutant organoids with early T3 addition. Thrb mutation completely suppressed the effects of T3, generating organoids with only S cones (wild type + T3, S = 4%, L/M = 96%; Thrb KO + T3, S = 100%, L/M = 0%; P < 0.0001) ( Fig. 3 , F to H). We conclude that T3 acts though Thrb to promote L/M cone fate and suppress S cone fate.
We confirmed the regulation of L/M-opsin expression through thyroid hormone signaling in a retinoblastoma cell line, which expresses L/Mopsin when treated with T3 ( fig. S2 , C and D) (34) . T3-induced activation of L/M-opsin expression was suppressed upon RNA interference knockdown of Thrb (fig. S2 , E and F), which is similar to the suppression observed in human organoids.
In organoids, early T3 addition not only converted cone cells to L/M fate but also dramatically increased cone density (Fig. 3, F and K) . Moreover, T3 acts specifically through Thrb to control cone density (Fig. 3, G and K) . Early T3 addition may increase cone density by advancing and extending the temporal window of L/M cone generation.
Together, these results demonstrate that T3 signals though Thrb to promote L/M cone fate and repress S cone fate in developing human retinal tissue.
Dynamic expression of thyroid hormone-regulating genes during development
Our data suggest that temporal control of thyroid hormone signaling determines the S-versus-L/M cone fate decision, in which low signaling early induces S fate and high signaling late induces L/M fate. Thyroid hormone exists largely in two states: thyroxine (T4), the most abundant circulating form of thyroid hormone, and T3, which binds thyroid hormone receptors with high affinity (31, 35) . Because the culture medium contains low amounts of T3 and T4, we hypothesized that the retina itself could modulate and/or generate thyroid hormone to control subtype fates.
Conversion of T4 to T3 occurs locally in target tissues to induce gene expression responses (36, 37) . Deiodinases-enzymes that modulate the levels of T3 and T4-are expressed in the retinas of mice, fish, and chickens (29, (38) (39) (40) (41) (42) . Therefore, we predicted that T3-and T4-degrading enzymes would be expressed during early human eye development to reduce thyroid hormone signaling and specify S cones, whereas T3-producing enzymes, carriers, and transporters would be expressed later in human eye development to increase signaling and generate L/M cones. To test these predictions, we examined gene expression across 250 days of organoid development. The expression patterns of thyroid hormoneregulating genes were grouped into three classes: changing expression ( Fig. 4A) , consistent expression (Fig. 4B ), or no expression ( Fig. 4C ). Deiodinase 3 (DIO3), an enzyme that degrades T3 and T4 (36) , was expressed at high levels early in organoid development but at low levels later (Fig. 4A ). Conversely, deiodinase 2 (DIO2), an enzyme that converts T4 to active T3 (36) , was expressed at low levels early but then dramatically increased over time (Fig. 4A) . We examined RNAseq data from Hoshino et. al (23) and found that developing human retinas display similar temporal changes in expression of DIO3 and DIO2 ( fig. S3A ). Deiodinase 1 (DIO1), which regulates T3 and T4 predominantly in the liver and kidney (43) , was not expressed in organoids or retinas ( Fig. 4C and fig. S3C ). Thus, the dynamic expression of Dio3 and Dio2 supports low thyroid hormone signaling early in development to generate S cones and high thyroid hormone signaling late to produce L/M cones.
Consistent with a role for high thyroid hormone signaling in the generation of L/M cones later in development, expression of transthyretin (TTR), a thyroid hormone carrier protein, increased during organoid and retinal development ( Fig.  4A and fig. S3A ) (23) . By contrast, albumin (ALB) and thyroxine-binding globulin (SERPINA7), other carrier proteins of T3 and T4, were not expressed in organoids or retinas ( Fig. 4C and fig. S3C ) (23) .
T3 and T4 are transported into cells via membrane transport proteins (44) . The T3/T4 transporters SLC7A5 and SLC7A8 increased in expression during organoid differentiation (Fig. 4A) . Additionally, two T3/T4 transporters, SLC3A2 and SLC16A2, were expressed at high and consistent levels throughout organoid development (Fig. 4B) . Other T3/T4 transporters (SLC16A10, SLCO1C1, and SLC5A5) were not expressed in organoids (Fig. 4C ), suggesting tissue-specific regulation of T3/T4 uptake. We observed similar expression patterns of T3/T4 transporters in human retinas ( fig. S3 , A to C) (23) .
We next examined expression of transcriptional activators and repressors that mediate the response to thyroid hormone. Consistent with Thrb expression in human cones (45) , expression of Thrb in organoids increased with time as cone cells were specified (Fig. 4A ). Expression of thyroid hormone receptor a (Thra) similarly increased with time ( Fig. 4A ). Thyroid hormone receptor cofactors, corepressor NCoR2 and coactivator MED1, were expressed at steady levels during organoid differentiation (Fig. 4B) . Similar tempo-ral expression patterns were observed in human retinas (fig. S3, A and B) (23) . Thus, our data suggest that expression of Thrb and other transcriptional regulators enables gene regulatory responses to differential thyroid hormone levels.
A complex pathway controls production of thyroid hormone. Thyrotropin-releasing hormone (TRH) is produced by the hypothalamus and other neural tissue. TRH stimulates release of thyroid-stimulating hormone a (CGA) and thyroidstimulating hormone b (TSHb) from the pituitary gland. CGA and TSHb bind the thyroid-stimulating hormone receptor (TSHR) in the thyroid gland. T3 and T4 production requires thyroglobulin (TG), the substrate for T3/T4 synthesis, and thyroid peroxidase (TPO), an enzyme that iodinates tyrosine residues in TG (46) . TRH was expressed in organoids and retinas, but the other players were not (Fig. 4, A to C, and fig. S3 , A to C) (23, 47, 48) , suggesting that the retina itself does not generate thyroid hormone; rather, it modulates the relative levels of T3 and T4 and expresses TRH to signal for thyroid hormone production in other tissues.
Therefore, the temporal expression of thyroid hormone signaling regulators supports our model that the retina intrinsically controls T3 and T4 levels, ensuring low thyroid hormone signaling early to promote S fate and high thyroid hormone signaling late to specify L/M fate (Fig. 4D ). Organoids provide a powerful system with which to determine the mechanisms of human development. Model organism and epidemiological studies generate important hypotheses about human biology that are often experimentally intractable. This work shows that organoids enable direct testing of hypotheses in developing human tissue.
Our studies identify temporal regulation of thyroid hormone signaling as a mechanism that controls cone subtype specification in humans. Consistent with our findings, preterm human infants with low T3/T4 have an increased incidence of color vision defects (49) (50) (51) (52) . Moreover, our identification of a mechanism that generates one cone subtype while suppressing the other, coupled with successful transplantation and incorporation of stem cell-derived photoreceptors in mice (53) (54) (55) (56) , suggests that the promise of therapies to treat human diseases such as color blindness, retinitis pigmentosa, and macular degeneration will be achieved in the near future.
Materials and methods summary
Cell lines H7 ESC (WA07, WiCell) and episomal-derived EP1.1 iPSC lines were used for differentiation.
WERI-Rb1 retinoblastoma cells were obtained from ATCC. Cell maintenance and organoid differentiation protocols are described in the supplementary materials.
CRISPR mutations
All mutations were generated in H7 ESCs. Cells were modified to express an inducible Cas9 element. Plasmids for guide RNA (gRNA) transfection were generated by using the pSpCas9(BB)-P2A-Puro plasmid modified from the pX459_V2.0 plasmid (62988, Addgene) by replacing T2A with a P2A sequence. Mutations were confirmed with polymerase chain reaction sequencing. Gene diagrams of deletions are displayed in fig. S2A . Detailed transfection procedures, gRNA sequences, and homology arm sequences are included in the supplementary materials.
Immunohistochemistry
Primary antibodies were used at the following dilutions: goat anti-SW-opsin (1:200 for organoids, 1:500 for human retinas) (Santa Cruz Biotechnology), rabbit anti-LW/MW-opsins (1:200 for organoids, 1:500 for human retinas) (Millipore), mouse anti-CRX (1:500) (Abnova), and mouse anti-Rhodopsin (1:500) (GeneTex). All secondary antibodies were Alexa Fluor-conjugated (1:400) and made in donkey (Molecular Probes). Detailed methods for fixation, microscopy, and image processing of organoids, retinas, and WERI-Rb1 cells are included in the supplementary materials.
Organoid age
Opsin expression time course to (G) (WT, n = 9 organoids; Thrb KO, n = 3 organoids; WT + T3, n = 6 organoids; Thrb KO + T3, n = 3 organoids. Tukey's multiple comparisons test: WT versus Thrb KO, P < 0.0001; WT versus WT + T3, P < 0.01; WT + T3 versus Thrb KO + T3, P < 0.0001). (I) Length of outer segments. WT, L/M n = 66 cells; WT, S n = 66 cells; Thrb KO, n = 50 cells (Tukey's multiple comparisons test, WT L/M versus WT S, P < 0.0001; WT L/M versus Thrb KO, P < 0.0001; WT S versus Thrb KO, not significantly different).
(J) Width of inner segments. WT, L/M n = 78 cells; WT, S n = 78 cells; Thrb KO, n = 118 cells (Tukey's multiple comparisons test, WT L/M versus WT S, P < 0.0001; WT L/M versus Thrb KO, P < 0.0001; WT S versus Thrb KO, not significantly different). (K) T3 acts through Thrb to increase total cone number. Quantification of density of S and L/M cones; WT, n = 6 organoids; Thrb KO, n = 3 organoids; WT + T3, n = 3 organoids; Thrb KO + T3, n = 3 organoids (Tukey's multiple comparisons test between total cone numbers, WT versus Thrb KO, not significantly different; WT versus WT + T3, P < 0.01; WT + T3 versus Thrb KO + T3, P < 0.0001).
taken at day 199 for each group, and one was taken at day 277 for each group. T3-treated organoids were taken at time points between day 195 and day 200 for different differentiations. For each treatment group and genotype, organoids were compared with control organoids grown in parallel.
RNA-seq time course
EP1 iPSC-derived organoids were analyzed at time points ranging from day 10 to day 250 of differentiation. We took samples at day 10 (n = 3 organoids), day 20 (n = 2 organoids), day 35 (n = 3 organoids), day 69 (n = 3 organoids), day 111 (n = 3 organoids), day 128 (n = 3 organoids), day 158 (n = 2 organoids), day 173 (n = 3 organoids), day 181 (n = 3 organoids), day 200 (n = 3 organoids), and day 250 (n = 3 organoids). RNA from individual organoids was extracted by using the Zymo Direct-zol RNA Microprep Kit (Zymo Research) according to manufacturer's instructions. Libraries were prepared by using the Illumina TruSeq stranded mRNA kit and sequenced on an Illumina NextSeq 500 with single 200-base pair reads.
RNA-seq time course analysis
Expression levels were quantified by using Kallisto (version 0.34.1) with the following parameters: "-b 100 -l 200 -s 10 -t 20-single". The Gencode release 28 comprehensive annotation was used as the reference transcriptome (57) . Transcripts per mil-lion (TPM) values (table S1) were then used to generate graphs in Prism and heatmaps in R by using ggplot2. The distributions of transcripts were plotted so as to identify the best low TPM cutoff ( fig. S5A ). The threshold was determined to be 0.7 log(TPM + 1)-5 TPM-and this value was used as an inflection point for the heatmaps. Heatmaps for fig. S3 , A to C, were made similarly, by using CPM values from Hoshino et. al ( fig. S5B ) (23) . were done in GraphPad Prism, with a significance cutoff of 0.01. Statistical tests are listed in figure legends. All error bars represent the SEM.
Measurements and quantification

